CATUG and SML Biopharm Sign Memorandum of Understanding to Boost mRNA Technology Development

Basel, Switzerland, December 4, 2024 – SML Biopharm, a pioneering Korean biopharmaceutical company focused on developing next-generation cancer vaccines and treatments for various indications, using mRNA platforms and advanced LNP delivery systems has entered agreement with CATUG, a global leader in CRO/CDMO services specializing in mRNA technology through Memorandum of Understanding (MoU).

Under the MoU, the two companies will leverage their complementary strengths to forge a collaborative alliance. Through the partnership, CATUG will bring in its extensive expertise in nucleic acid and LNP research, development and manufacturing, while SML Biopharm will leverage on their innovative platform towards various application of mRNA-LNP technology as well as its strong influence towards Korean market. Together, the partnership seeks to optimize mutual benefits and drive growth for both organizations.

“This MoU represents a significant step forward for both our companies.” said Jae-Hwan Nam, CEO of SML Biopharm. “By harnessing CATUG’s expertise in mRNA and LNP manufacturing, we are confident this partnership will enable us to advance new drug candidates and push forward the development of those already in our pipeline. Together, we aim to drive innovation and contribute to the biohealth industry, creating new opportunities for both parties.”

Lin Jin, co-Founder and President of CATUG, echoed these sentiments, stating “We are excited to partner with SML Biopharm, as we see tremendous potential in this collaboration. By combining our capabilities with SML Biopharm's expertise and influence in Korean market, we aim to accelerate the development of next-generation treatments that have the potential to transform patient care and open new channels for greater access towards the Korean Market.”

Through this collaboration, SML Biopharm and CATUG will focus on joint research and development initiatives, and also the marketing and sales activities towards life science tools and contract services. The signing of this MoU marks a significant milestone for both companies to expand their presence in global markets, delivering cutting-edge solutions in mRNA-based therapeutics and advanced drug delivery systems.

About SML Biopharm
SML Biopharm is a pioneering South Korean biopharmaceutical company at the forefront of mRNA vaccine and therapeutic development, and commercialization of next-generation cancer vaccines and treatments for various diseases. SML Biopharm strives to deliver breakthrough therapies by advancing cutting-edge mRNA platforms and novel LNP drug delivery systems, committed to promote a healthier future for all.

For more information, please visit http://www.smlbiopharm.com

About CATUG
Headquartered in Basel, Switzerland, CATUG is known for its rapid and flexible approach to providing contract research, development, and GMP manufacturing services across the RNA therapeutic pipeline. The company specializes in the development of plasmid DNA, mRNA, siRNA, and lipid nanoparticles, and offers a wide spectrum of analytical services for sample QC.

For more information, please visit https://www.catug.bio